What Patients Should Know About Ozempic and Gastroparesis Risk
From General Health Education to Targeted Risk Communication
If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication is causing delayed gastric emptying. This concern reflects a long-recognized principle in pharmacovigilance: even well-studied drugs can reveal new adverse effects as real-world use expands. Here we review the prescribing information and clinical evidence on Ozempic-associated gastroparesis.
Understanding Gastroparesis and Its Link to Ozempic
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies the gastrointestinal adverse reactions commonly reported with Ozempic use. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which aligns with the known effect of GLP-1 receptor agonists on gastric motility.
Mechanistic Pathway and Warning Adequacy
The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action on GLP-1 receptors in the gastrointestinal tract, which delays gastric emptying. While this effect is intended for glycemic control, it can become pathological in some patients, leading to persistent symptoms of gastroparesis even after discontinuation of the drug. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation but may persist or worsen with continued use. In clinical trials, gastrointestinal adverse reactions were most common during the initial weeks of treatment, but some patients may experience prolonged effects. Regarding the adequacy of warnings, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported, but it does not address the risk of delayed gastric emptying leading to gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in labeling may be relevant for patients who develop gastroparesis after using Ozempic, as they may argue that the warnings were insufficient to alert them to this specific risk.
Statute of Limitations for Ozempic Claims in Ohio
For affected patients in Ohio considering a settlement, the statute of limitations is a critical factor. In Ohio, personal injury claims generally must be filed within two years from the date the injury is discovered or should have been discovered with reasonable diligence. For Ozempic-related gastroparesis, the clock typically starts when the patient is diagnosed with gastroparesis and becomes aware of the potential link to the medication. This timeline can be complicated by the gradual onset of symptoms and the need to rule out other causes. Patients should consult with an attorney to determine the specific filing deadline in their case. Settlement-related considerations for affected patients include the strength of the evidence linking Ozempic to gastroparesis, the severity of the injury, and the adequacy of the warnings provided by the manufacturer. The clinical trial data show a clear dose-response relationship for gastrointestinal adverse reactions, which supports a causal link. However, the lack of a specific warning about gastroparesis in the label may strengthen claims of inadequate warnings. Patients should also consider the timeline between exposure and harm, as longer durations of use may increase the likelihood of developing gastroparesis. In summary, Ozempic is associated with a dose-dependent increase in gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with the pathophysiology of gastroparesis. The prescribing information does not specifically warn about gastroparesis, which may be relevant for legal claims. In Ohio, the statute of limitations for such claims is generally two years from discovery of the injury. Patients should seek legal advice promptly to preserve their rights.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in Ohio?
In Ohio, personal injury claims generally must be filed within two years from the date the injury is discovered or should have been discovered with reasonable diligence. For Ozempic-related gastroparesis, the clock typically starts when the patient is diagnosed with gastroparesis and becomes aware of the potential link to the medication. Patients should consult with an attorney to determine the specific filing deadline in their case.
Does Ozempic's prescribing information warn about gastroparesis?
The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions have been reported, but it does not address the risk of delayed gastric emptying leading to gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in labeling may be relevant for legal claims.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.